News
PTJA05 – enasidenib for the treatment of adult patients with relapsed or refractory acute myeloid leukaemia (AML) with an isocitrate dehydrogenase 2 (IDH2) mutation
On 6 Dec 2019, Celgene officially notified the Committee for Medicinal Products for Human Use (CHMP) that it wishes to withdraw its application for a
PTJA05 – enasidenib for the treatment of adult patients with relapsed or refractory acute myeloid leukaemia (AML) with an isocitrate dehydrogenase 2 (IDH2) mutation
On 6 Dec 2019, Celgene officially notified the Committee for Medicinal Products for Human Use (CHMP) that it wishes to withdraw its application for a
OTCA21 Updated Final Project Plan and related documents now available
EUnetHTA is pleased to announce that the final project plan, now updated with new dates for publication of the final report, and comments from external
Patient group input requested for a new Joint Assessment on a medicinal product for tuberculosis.
EUnetHTA deems patient involvement very important in the production of Joint Assessment reports. We recognise that patients and those who support them have unique knowledge
Open Call for Patient Group Input – Collaborative Assessment of (bariatric) surgical methods for treatment of morbid obesity
EUnetHTA recently started a new Collaborative Assessment of different surgical methods to treat morbid obesity To find out about participation, please read more here. Input submissions
EUnetHTA 2020 Forum
The EUnetHTA 2020 Forum was originally planned to be held on 2nd April at Zorginstituut Nederland (ZIN), the Dutch Health Care Institute, in Diemen near
EUnetHTA releases the second version of its methodological guideline “Process of information retrieval for systematic reviews and health technology assessments on clinical effectiveness”
The aim of this methodological guideline is to provide an up-to-date and transparent overview of the whole information retrieval process for Systematic reviews and HTAs
OTCA24 – Final Project Plan and related documentation now available.
EUnetHTA is pleased to announce that the final project plan and related documents from external experts for the Other Technologies Collaborative Assessment OTCA24 “The 24-hour
Important Event Dates – 2020/21
We would like to confirm some dates for key EUnetHTA events throughout the remainder of JA3. Please ensure to put these in your agenda: 25-26
PTJA09 – ‘Brolucizumab for the treatment of adults with neovascular (wet) age-related macular degeneration (AMD)’ project plan now available
The final project plan of the relative effectiveness of ‘Brolucizumab for the treatment of adults with neovascular (wet) age-related macular degeneration (AMD)’ is now available
